Form 4: Director Luke Evnin Sells Werewolf Therapeutics Shares

Director Luke Evnin of Werewolf Therapeutics, Inc. sold 205,911 shares of common stock over three days in late April 2026.

Summary

• Director Luke Evnin executed a series of sales of Werewolf Therapeutics (HOWL) common stock between April 27 and April 29, 2026.
• A total of 205,911 shares were sold through various MPM BioImpact-affiliated entities.
• The sales were conducted pursuant to a Rule 10b5-1 trading plan established on March 26, 2026.
• Following these transactions, the reporting person maintains an indirect beneficial ownership of 1,953,949 shares.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as neutral-to-negative, as consistent insider selling, even when pre-planned, often creates downward pressure on the stock price.

Positives

• The transactions were executed under a pre-established Rule 10b5-1 trading plan, which typically indicates scheduled divestment rather than reactive selling based on non-public information.

Negatives

• The director reduced their stake in the company by over 200,000 shares.
• The sales occurred at declining weighted average prices, ranging from $0.85 on April 27 to $0.69 on April 29.

Risks

• Continued selling pressure from major institutional insiders may negatively impact market sentiment and share price performance.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this disclosure.

Industry Context

StockSavvy.ai notes that insider selling in the biotechnology sector is common as venture capital firms reach the end of their investment horizons or rebalance portfolios, though it can signal a lack of near-term confidence to retail investors.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders to avoid allegations of insider trading while liquidating equity positions.

Related Party Transactions

• The shares were sold by various MPM BioImpact-affiliated entities including MPM Asset Management LLC, MPM BioVentures 2014, L.P., and MPM Oncology Innovations Fund, L.P.

Stakeholder Impact

• Shareholders may experience increased volatility due to the volume of shares being sold into the market.

Next Steps

• Monitor future Form 4 filings to determine if the Rule 10b5-1 plan continues to result in further share liquidations.

Key Dates

Recommendation

While the sales are pre-planned, the consistent divestment by a director at declining price points suggests a lack of immediate upside conviction, warranting a hold position until further operational catalysts emerge.

Keywords

Werewolf Therapeutics, HOWL, Insider Trading, Form 4, Biotech, Rule 10b5-1